Does Rising Revenue But Weaker Earnings Change The Bull Case For SCHOTT Pharma KGaA (XTRA:1SXP)?

• SCHOTT Pharma AG & Co. KGaA recently reported third-quarter 2026 results, with sales rising to €281.76 million while net income declined to €38.83 million versus a year earlier.
• Over the first nine months of the fiscal year, the company grew revenues to €769.83 million but saw earnings per share from continuing operations slip to €0.68, highlighting pressure on profitability despite higher demand.
• We’ll now explore how higher sales but reduced earnings in the latest results may reshape SCHOTT Pharma’s investment narrative and risk balance.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

SCHOTT Pharma KGaA Investment Narrative Recap

To own SCHOTT Pharma today, you need to believe that its shift toward higher value injectable packaging can offset pressure in traditional vials and polymer syringes. The latest Q3 2026 results, with higher sales but weaker earnings, reinforce that the near term catalyst is mix and margin improvement, while the biggest risk remains that heavy capex and softer segments keep profitability under strain. This quarter does not radically alter that risk balance, but it underlines it.

The most relevant recent development alongside these results is the June 2026 expansion of U.S. vial capacity in Lebanon, Pennsylvania, supported by BARDA funding. This directly ties into the high value solutions story, increasing output of adaptiQ RTU and EVERIC pure vials at a time when margins are under pressure. While this build out could support the growth side of the thesis, it also adds to the capex burden that is already weighing on free cash flow and earnings.

Yet beneath the higher sales and new capacity, there is a less visible risk investors should be aware of that...

Read the full narrative on SCHOTT Pharma KGaA (it's free!)

SCHOTT Pharma KGaA's narrative projects €1.2 billion revenue and €189.8 million earnings by 2029. This requires 6.6% yearly revenue growth and about €47 million earnings increase from €142.8 million today.

Uncover how SCHOTT Pharma KGaA's forecasts yield a €20.43 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Some analysts were already much more optimistic, expecting revenue to reach about €1.3 billion and earnings around €214 million, but Q3’s weaker EPS and continued capex strain could challenge that view or make it look even more ambitious, depending on how you weigh the heavy spending and reliance on a concentrated customer and product base.

Explore 4 other fair value estimates on SCHOTT Pharma KGaA - why the stock might be worth 7% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your SCHOTT Pharma KGaA research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free SCHOTT Pharma KGaA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SCHOTT Pharma KGaA's overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com